GLP-1 Insurance Coverage Mandates by State (2026)

Table 1. Jurisdictions that change the count or are easiest to misclassify, August 1, 2026

GLP-1 insurance coverage mandates by state: 2026 data and counts

Answer: North Dakota is the one state in this review whose private-market EHB benchmark expressly names GLP-1/GIP therapy. New Mexico and North Carolina have broader obesity-prescription-drug benefits. The remaining tracked actions belong to different legal categories and cannot be added into one honest "mandate states" total.

Thirty-nine of the 51 jurisdictions have no tracked GLP-1-specific action under this methodology. The other 12 include actual requirements, offers, authorizations, administrative programs, exclusions, and high-risk false positives.

Table 2. Classification counts at the August 1, 2026 cutoff

That overlap is not a technical nuisance. It is the answer. Adding the categories together creates a large headline and destroys the legal meaning of the number.

What counts as a GLP-1 coverage mandate?

Answer: We tracked seven statuses because the word "mandate" can be used for actions that have different legal effects. The status determines whether coverage is automatic, merely available for purchase, dependent on an appropriation, left to an agency, limited to an annual program, expressly excluded, or not law at all.

Table 3. The seven-status classification framework

Two rules are applied without exception. A must-offer provision is not counted as automatic coverage. An authorization is not counted as a mandate. Neither rule is complicated. Both prevent basic counting errors on this topic.

The full 51-jurisdiction GLP-1 coverage ledger

Answer: Every state and the District of Columbia appears below with its classification, the coverage system affected, the controlling authority, the operative status, and an employer-market self-insurance measure. Negative rows report the result of this review; they do not claim that no insurer, employer, Medicaid contractor, or public plan in the state ever covers a GLP-1.

The complete 21-field dataset adds separate commercial-market, Medicaid, and state employee-plan fields; document status; plans not reached; primary and secondary source URLs; verification date; confidence; publish status; and change-log notes.

Dataset downloads: CSV · JSON

Table 4. GLP-1 insurance coverage mandates by state, August 1, 2026

"No tracked action identified" means the review found no enacted GLP-1-specific requirement, authorization, administrative program, express exclusion, or live high-risk proposal under the stated scope at the cutoff. It does not mean insurers in that jurisdiction never cover GLP-1s. Voluntary formulary coverage can exist and is not what this dataset measures.

What does this GLP-1 mandate dataset show — and what does it not show?

Answer: This is a dated map of legal requirements, benchmark benefits, public-plan actions, exclusions, and high-risk false positives. It does not determine whether a specific person, product, dose, employer plan, Medicaid managed-care plan, or pharmacy claim is covered today.

The dataset shows the legal instrument, the coverage system, the controlling version, whether the action is operative, and the primary source behind the classification.

It does not show your formulary, your employer's benefit election, your Medicaid managed-care organization's criteria, your clinical eligibility, or the result of a prior-authorization request. Unless the controlling authority limits them, coverage may still be subject to medical-necessity review, prior authorization, cost sharing, tiering, quantity limits, and formulary rules. North Dakota's benchmark is a coverage requirement; it is not a promise that every GLP-1 product will be covered at every price.

This dataset is limited to obesity and weight-management coverage. Coverage for type 2 diabetes, cardiovascular-risk reduction, obstructive sleep apnea, and other indications follows separate benefit and indication rules and is outside the count.

How was the 51-jurisdiction dataset built and verified?

Answer: The positive and high-risk rows were classified from final statutes, enrolled acts, current amended bills, CMS-approved benchmark documents, and official public-plan materials. Drafts, failed bills, optional offers, authorizations, administrative programs, exclusions, and appropriation-contingent laws remain visible instead of being silently folded into a single mandate number.

Source hierarchy

1. Final codified statute or enrolled session law
2. Final CMS-approved EHB benchmark document and official insurance-department material
3. Official Medicaid bulletin, state plan, preferred drug list, or agency policy
4. Official state employee-plan administrator material
5. Official bill history and current amended text
6. Third-party policy analyses for discovery and cross-checking only, never as substitutes for controlling state authority

Inclusion and classification rules

• A row counts as an express private-market GLP-1 requirement only when final operative benchmark or legal authority expressly names GLP-1/GIP or equivalent product-specific coverage for the reviewed indication.
• A broader obesity-drug EHB benefit is a separate category. It may encompass FDA-approved GLP-1 drugs, but it does not prove that every product, dose, or presentation must be covered.
• A must-offer provision is not recorded as automatic coverage.
• A Medicaid or CHIP authorization is not recorded as a mandate.
• An appropriation-contingent law remains enacted but not operative until the trigger is verified.
• Administrative or annual public-plan coverage is recorded as coverage policy, never converted into a standing statutory mandate.
• A final exclusion controls over a draft addition.
• A current amended bill controls over introduced or earlier language.

How negative rows were handled

Negative rows are scoped audit conclusions. For those jurisdictions, we checked the CMS benchmark directory and current benchmark status, then reviewed official legislative and state sources for GLP-1, anti-obesity medication, obesity-treatment, Medicaid, and public employee-plan actions within the dataset's scope. A negative row is not an absolute legal opinion and does not claim that every possible plan excludes treatment.

Original calculations in this page

• 39 no-tracked-action rows = 51 audited jurisdictions minus 12 jurisdictions with a tracked action or high-risk false positive.
• Three obesity-drug EHB benchmarks = North Dakota, New Mexico, and North Carolina, classified from their benchmark materials.
• One express GLP-1/GIP private-market benchmark = North Dakota.
• 12 post-2019 benchmark approvals across 11 jurisdictions = the complete CMS approval list for plan years 2020 through 2027.
• 37.3 percentage-point state spread in self-insurance = Nebraska's 72.6% minus Hawaii's 35.3% in the 2024 MEPS-IC table.

What do North Dakota, New Mexico, and North Carolina require in private ACA plans?

Answer: All three states have obesity-prescription-drug coverage in the benchmark used by non-grandfathered individual and small-group plans. North Dakota expressly names GLP-1 and GIP therapy. New Mexico and North Carolina use broader obesity-drug language without guaranteeing a particular GLP-1 product.

An Essential Health Benefits benchmark plan defines the minimum benefit package for non-grandfathered individual and small-group coverage in a state. It does not automatically govern large-group plans, private-employer self-funded plans, Medicaid, or public employee plans.

North Dakota: the benchmark that names GLP-1 and GIP drugs

North Dakota's insurance department states that the benchmark covers the use of GLP-1 and GIP drugs as therapy for the prevention of diabetes and treatment of insulin resistance, metabolic syndrome, or morbid obesity. The change applies to non-grandfathered individual and small-group plans beginning January 1, 2025. The department also states that the benchmark change does not apply to PERS merely because it is part of the benchmark. Read the North Dakota Insurance Department benchmark materials.

The same source says issuers may use reasonable medical-management techniques, including prior authorization, and may impose cost sharing subject to federal limits and nondiscrimination requirements. North Dakota therefore belongs in the express requirement column, but not in a "guaranteed product with no restrictions" column. The benchmark materials use the term morbid obesity but do not supply a BMI threshold in the cited coverage description.

New Mexico: medically necessary drugs for obesity and morbid obesity

New Mexico's benchmark covers weight-loss programs and prescription drugs when medically necessary for obesity and morbid obesity. The benefit became part of the benchmark for plan year 2022. Read the New Mexico benchmark plan.

The wording is broader by indication than North Dakota's morbid-obesity phrase, but it does not name GLP-1s or promise every product. It creates an obesity-prescription-drug benefit and leaves product-level coverage to the plan's compliant formulary and medical-management rules.

North Carolina: the prescription-drug provision is in the full plan document

North Carolina's full benchmark plan document provides coverage for FDA-approved prescription drugs for short- and long-term treatment of clinical obesity. Read the North Carolina benchmark plan document.

The high-level "Weight Loss Programs" summary and the underlying prescription-drug provision are separate pieces of the benchmark. The full plan document supports the obesity-drug classification. That is why this row is based on the plan text rather than a summary label taken in isolation.

Why a benchmark benefit does not guarantee Wegovy or Zepbound

A benchmark establishes a covered benefit floor. It does not automatically remove formulary selection, prior authorization, quantity limits, cost sharing, or other reasonable medical-management rules. The legally accurate statement is that the benchmark includes an obesity-prescription-drug benefit — not that every GLP-1 product must be covered for every enrollee.

How do we know the benchmark count is complete?

Answer: CMS publishes the complete list of states whose EHB benchmarks changed after plan year 2019. That list closes the universe of post-2019 updates. The complete obesity-drug count also requires the legacy plan-year-2017 benchmark documents, which is where North Carolina's prescription-drug provision appears.

Table 5. Every CMS-approved EHB benchmark update, plan years 2020–2027

That is 12 approvals across 11 jurisdictions. Three post-2019 update files matter directly to this obesity-drug analysis: New Mexico and North Dakota added relevant benefit language, while Alaska's final update retained an obesity-treatment exclusion. States that did not use the post-2019 update process continue with their plan-year-2017 benchmark; the legacy review is therefore a separate layer, not something the approval list replaces.

This is the exhaustiveness test: a claimed post-2019 benchmark addition must appear in the CMS approval list, while a claimed legacy benefit must be supported by the controlling legacy plan document.

Does Colorado's 2027 law require large-group plans to cover GLP-1s?

Answer: No. Colorado's law requires affected carriers to offer a policyholder the option to purchase anti-obesity-drug coverage that includes at least one FDA-approved GLP-1 medication beginning January 1, 2027. The policyholder must elect the option; the drug benefit is not automatically included in every large-group plan.

Colorado enacted SB 25-048 in 2025. The law treats the drug benefit differently from several other obesity-treatment services. It also contains a premium-sufficiency exception tied to whether premiums would cover the expected benefit cost.

Colorado had considered a broader must-cover proposal in SB 24-054. That bill did not become law. The enacted 2025 measure moved the drug provision into a must-offer structure.

That sequence is useful because it shows the difference between legislative attention and operative coverage. Colorado acted, but it did not enact automatic GLP-1 coverage for every affected large-group policy.

Which states acted through Medicaid or public employee plans?

Answer: Illinois has a currently operative statutory state employee-plan mandate. Louisiana has an appropriation-contingent Medicaid requirement and a future voluntary Office of Group Benefits plan. Maryland and Connecticut enacted authorizations rather than mandates. Connecticut and Florida also operate coverage through administrative or annual public-plan programs.

Illinois: an operative statutory public employee-plan mandate

Beginning July 1, 2024, 5 ILCS 375/6.11C requires the State Employees Group Insurance Program to cover medically necessary injectable medicines prescribed on-label or off-label to improve glucose or weight loss for qualifying adults with specified diagnoses that include obesity. This is the one currently operative statutory public employee-plan mandate identified in the review.

Louisiana: one contingent Medicaid law and one voluntary public plan

Louisiana Act 898 requires Medicaid to cover FDA-approved medically necessary weight-loss medications, permits prior authorization, and bars step therapy. The substantive coverage section becomes operative only when a separate act containing a specific implementation appropriation takes effect.

There is no fixed operative date in the coverage section. Until the appropriation trigger is verified, the correct classification is enacted but not yet operative.

Separately, Louisiana Act 749 requires the Office of Group Benefits to offer a voluntary comprehensive weight-management plan beginning January 1, 2027. The participant or dependent pays 100% of the premium, and the act does not require existing OGB plans to change their medical-necessity, utilization-management, or formulary rules.

Maryland: permission, not compulsion

Maryland SB 496 / Chapter 866 authorizes the Maryland Medical Assistance Program to provide comprehensive obesity-treatment coverage beginning January 1, 2027. The enacted text uses "may," not a command that the benefit be activated. The act takes effect October 1, 2026. An authorization is a real legislative action. It is still not a mandate.

Connecticut: administrative coverage, reporting, and a separate authorization

Connecticut's state employee plan covers anti-obesity medications through designated medical weight-management programs. Care Compass describes the current program, while Conn. Gen. Stat. § 5-259h requires reporting on GLP-1 utilization and cost rather than creating the underlying benefit.

Connecticut's Public Act 25-168 also allows, rather than requires, the Department of Social Services to cover specified obesity treatments under Medicaid and CHIP. That authorization belongs in the public-program column, not the mandate column. The same 2025 act regulates utilization management in specified circumstances. Its BMI-40 step-therapy exception is tied to a licensed provider's certification that the person will undergo a surgery requiring anesthesia within six months.

Florida: a real program, but not a standing statewide mandate

Florida's 2026 Benefit Guide says the state group plan's Weight Management Program provides a wellness program and FDA-approved weight-management medications with a Tier 3 copay. The 2026 program is available to 2,800 members, runs January 1 through December 31, and remains subject to legislative approval. Florida's HB 977 and related SB 1070 would have expanded standing state group coverage. Both died on March 13, 2026.

Why a Medicaid coverage count is not a mandate count

KFF reported that 13 state Medicaid fee-for-service programs covered GLP-1s for obesity as of January 2026. That is a measure of administrative coverage at a dated point, not a count of statutory mandates. Federal Medicaid law allows states to exclude agents used for weight loss, which is why a program can add or remove coverage without a new standing mandate. See 42 U.S.C. § 1396r-8.

Which state actions are easiest to misclassify as GLP-1 mandates?

Answer: Final exclusions, optional offers, authorizations, annual programs, appropriation triggers, failed bills, and superseded bill text can produce false mandate counts. Alaska, Arkansas, California, Colorado, Connecticut, Florida, Louisiana, and Maryland each illustrate a different failure mode.

Alaska: a final exclusion controls over a draft

Alaska's final 2026 benchmark says benefits are not provided for surgical and pharmaceutical treatment of obesity or morbid obesity and states that the exclusion applies to all obesity drugs and supplements. Read the final Alaska benchmark. A draft that contemplated a different benefit does not control.

Arkansas: obesity treatment with the drugs carved out

Arkansas Act 628 of 2025 requires specified severe-obesity treatment services. It then expressly says neither Medicaid nor affected private insurers are required to cover injectable drugs used to lower glucose levels or other drugs prescribed for weight loss. Arkansas has an obesity-treatment mandate. It does not have a GLP-1 coverage mandate under this act.

California: use the current amended text

California's SB 1089 previously contained a CalPERS coverage-offer provision. The June 18, 2026 amended version struck that language. The current bill addresses drug-production and pricing partnerships; it does not create the earlier coverage offer.

Colorado: must offer is not must cover

Colorado requires an option to be offered to affected large-group policyholders. It does not require every affected policyholder to buy the option. Counting Colorado as automatic large-group GLP-1 coverage erases the central term of the law.

Connecticut and Maryland: "may" is not "shall"

Both states enacted public-program authorizations. Those actions create legal permission and implementation paths. They do not themselves compel activation of the benefit.

Florida: an annual program is not permanent law

Florida has a current 2026 Weight Management Program, but it is capped at 2,800 members and subject to annual legislative approval. The 2026 bills that would have created broader standing coverage died.

Louisiana: enacted does not always mean operative

Louisiana enacted a Medicaid requirement, but the coverage section waits for a specific appropriation. Reporting it as currently operative before the trigger occurs changes the law's effect.

A recurring counting error

A Medicaid program coverage map answers "which programs cover treatment now?" A mandate tracker answers "which governments legally require which coverage systems to provide treatment?" Both are useful. They are not the same dataset.

Do state GLP-1 mandates reach every health plan?

Answer: No. Private-employer self-funded plans are generally outside state insurance benefit mandates, and EHB benchmark requirements are limited to non-grandfathered individual and small-group coverage. In 2024, 57.0% of private-sector enrollees in employer plans were in self-insured plans, with state estimates ranging from 35.3% in Hawaii to 72.6% in Nebraska.

A self-insured plan is one where the organization offering the plan assumes some or all of the financial risk for claims. The organization may hire an insurer or third-party administrator to run the plan, so an insurance-company logo on the card does not by itself tell you whether the benefit is state-regulated. AHRQ defines self-insurance here.

Table 6. Self-insured employer-plan enrollment: national figure, extremes, and tracked states

The Hawaii-to-Nebraska spread is 37.3 percentage points. That is original arithmetic from the federal table. These percentages do not equal the exact share reached by each mandate. They describe self-insurance among private-sector employer-plan enrollees. EHB benchmarks also apply to the individual market and only to the small-group segment of employer coverage.

What changes for state-required benefits in plan year 2028?

Answer: The 2027 federal payment rule restores a four-part test for deciding when a state must defray the cost of a state-required benefit beginning in plan year 2028. A benchmark selection or update does not, by itself, count as the triggering state action, but a separate statute, regulation, or other qualifying state action can.

Under the HHS Notice of Benefit and Payment Parameters for 2027, a state-required benefit is treated as in addition to EHB for defrayal purposes when all four conditions are met:

1. The requirement results from state action taken after December 31, 2011.
2. It applies to the individual or small-group market.
3. It is specific to care, treatment, or services that must be covered.
4. It is not required for compliance with federal law.

CMS clarified that selecting or updating an EHB benchmark does not by itself constitute the state action that triggers the test. Separate legislation, regulation, guidance, or another state action can still require the benefit.

This page does not resolve how that test applies to North Dakota's GLP-1 benefit. That requires a separate analysis of the benchmark update and any related state legal instruments against all four federal conditions. Beginning in 2028, a state considering a new individual- or small-group GLP-1 requirement must analyze the four-part defrayal test.

What changed in state GLP-1 coverage policy in 2025 and 2026?

Answer: The period produced substantial legislative activity but very few operative blanket mandates. The enacted outcomes split into a private benchmark requirement, a large-group optional offer, public-program authorizations, an appropriation-contingent Medicaid law, annual public-plan coverage, and express exclusions.

The clearest verified changes were:

• Colorado enacted a must-offer drug benefit after an earlier must-cover proposal failed.
• Louisiana enacted a Medicaid requirement that waits on an appropriation and a separate voluntary OGB plan beginning in 2027.
• Maryland and Connecticut enacted public-program authorizations rather than mandates.
• Florida continued a capped annual state employee program while broader 2026 bills died.
• California's remaining 2026 bill had its CalPERS coverage-offer language struck from the current version.
• KFF's fee-for-service Medicaid count moved from 16 programs in October 2025 to 13 in January 2026 after four eliminations and North Carolina's elimination-and-reinstatement sequence.

The plain result is that "states acted" and "states mandated automatic coverage" are not interchangeable statements. The reviewed actions largely landed in narrower legal categories.

Limitations

This dataset is designed to make the boundary visible rather than hide it.

• –This is not a formulary lookup or benefit determination. It cannot tell you whether a specific prescription will be covered.
• –A coverage requirement may still permit medical-necessity review, prior authorization, cost sharing, tiering, quantity limits, and formulary controls unless the controlling authority limits them.
• –Broad obesity-drug language does not guarantee a specific product, dose, or presentation.
• –Private-employer self-funded plans are generally outside state insurance benefit mandates. Public self-funded plans and federal requirements require separate analysis.
• –EHB benchmark rules reach non-grandfathered individual and small-group coverage, not every fully insured market.
• –Medicaid fee-for-service and managed-care criteria may differ within the same state.
• –Administrative public-plan coverage can change without a new statute. Florida's program is annual; Connecticut's coverage terms are plan policy.
• –Pending legislation can change after the cutoff. California's row is version-specific.
• –Negative rows are scoped evidence-review findings, not declarations that no relevant legal instrument could exist anywhere.
• –This dataset excludes diabetes-only, cardiovascular, sleep-apnea, and other non-obesity indications.
• –The North Carolina row rests on the full benchmark plan document, not the high-level program summary alone.
• –The plan-year-2028 section reports the federal rule and leaves state-specific application unresolved. It is not a legal opinion.
• –The MEPS-IC self-insurance column is contextual. It is not an estimate of the exact population reached by an EHB or public-program rule.
• –This page is educational. It is not legal advice, medical advice, or an individual coverage determination. The controlling plan document, insurer or public-program policy, and final state or federal authority govern a particular case.

Frequently asked questions

Primary sources

Federal

• Centers for Medicare & Medicaid Services — Information on Essential Health Benefits Benchmark Plans
• HHS Notice of Benefit and Payment Parameters for 2027
• Agency for Healthcare Research and Quality — MEPS-IC Data Tools
• 42 U.S.C. § 1396r-8 — Medicaid prescription-drug provisions

State

• North Dakota Insurance Department — 2025 EHB benchmark materials
• New Mexico EHB Benchmark Plan
• North Carolina EHB benchmark plan document
• Alaska 2026 EHB Benchmark Plan
• Illinois Compiled Statutes, 5 ILCS 375/6.11C
• Colorado SB 25-048 / Chapter 365
• Louisiana Act 898
• Louisiana Act 749
• Maryland SB 496 / Chapter 866
• Arkansas Act 628 of 2025
• Connecticut GLP-1 reporting statute (Conn. Gen. Stat. § 5-259h)
• Connecticut Public Act 25-168 summary
• Connecticut Care Compass anti-obesity medication program
• Florida 2026 Benefit Guide
• Florida HB 977 status
• California SB 1089 current bill page

Context and cross-checking

• KFF — Medicaid Coverage of and Spending on GLP-1s